Advancing Oncology with IsoDDE Technology
Isomorphic Labs Starts Human Trials for AI Drugs
The Alphabet spinoff aims to accelerate drug discovery in oncology using proprietary IsoDDE technology.
A high-tech digital display showing a glowing 3D molecular structure and DNA helix in a modern laboratory environment.
Photo: Avantgarde News
Isomorphic Labs, an Alphabet spinoff, has launched human trials for drugs designed using artificial intelligence [1]. The company, which originated from Google DeepMind, is testing drug candidates specifically for oncology [2]. This development marks a transition from laboratory modeling to direct clinical application [3].
The firm utilizes its proprietary IsoDDE technology to streamline the discovery process [1]. This engine aims to increase the success rate of trials by predicting molecular interactions in humans [2]. These results could define the next decade of pharmaceutical innovation [3].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
thenews.com.pk
https://www.thenews.com.pk/latest/1400311-ai-drug-breakthrough-google-deepmind-spinoff-isomorphic-labs-begins-human-trials
- 2.↗
mlq.ai
https://mlq.ai/news/isomorphic-labs-launches-human-trials-for-ai-designed-drugs/
- 3.↗
startupfortune.com
https://startupfortune.com/isomorphic-labs-is-putting-ai-designed-drugs-into-humans-and-the-results-will-define-a-decade/
Related stories
View all
Topics
About the author
Avantgarde News Desk covers advancing oncology with isodde technology and editorial analysis for Avantgarde News.